CEVIRA, a non-invasive therapy for cervical precancerous lesions, approved in China by Asieris Pharmaceuticals.

Photocure ASA, a leading player in bladder cancer treatment (OSE: PHO), has reported through its partner Asieris Pharmaceuticals (SSE: 688176) that APL-1702, known as CEVIRA®, has obtained the Drug Registration Certificate. This significant milestone was achieved as of March 3, 2026, marking a major advancement for the companies involved.